Rilonacept Regeneron (previously Arcalyst)

RSS

rilonacept

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Rilonacept Regeneron has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 30/10/2012

Authorisation details

Product details
Name
Rilonacept Regeneron (previously Arcalyst)
Agency product number
EMEA/H/C/001047
Active substance
Rilonacept
International non-proprietary name (INN) or common name
rilonacept
Therapeutic area (MeSH)
Cryopyrin-Associated Periodic Syndromes
Anatomical therapeutic chemical (ATC) code
L04AC08
Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance.

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation

Publication details
Marketing-authorisation holder
Regeneron UK Limited
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
22/10/2009
Contact address
40 Bank Street
London
E14 5DS
United Kingdom

Product information

27/06/2012 Rilonacept Regeneron (previously Arcalyst) - EMEA/H/C/001047 - S/0006

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Rilonacept Regeneron is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), in adults and children aged 12 years and older.

Assessment history

How useful was this page?

Add your rating